Dermoid cysts of the oral cavity are rare. When they do occur, the most common site is the floor of the mouth. Intralingual dermoid cysts are even more rare, and until now, there were only 15 such reports in the Englishlanguage literature. In this article, we desc ribe two additional cases . Magnetic resonance imaging is extremely helpful in establishing a differential diagnosis. Surgical excision is recommendedto correct deglutition and speec h problems. Its rarity notwithstand ing, dermoid cyst should be considered in the diffe rentia l diagnosis of tongue masses in the you nger population.
Introduction
Dermoid cysts of the oral cavity rarely occur in the tongue. To date, only 15such cases have been reported. In this article , we report two additional cases of intralingual dermoid cyst, and we discus s the mana gement of this lesion.
Case reports
Case 1. A 5-month-old boy was admitted with a I-week history of irritability, poor feeding, and fever. He had previously been treated with oral antibiotics and eardrops. The patient was the product of a full-term pregnancy and a normal, spontaneous vaginal delivery. He had no other significant medical history.
On admission, the patient ' s temp erature was 100.9°F. The physical exa mination was remarkable for an enlarged tongue, with induration of the ventral surface. The floor of the mouth was not elevate d or firm. Pertin ent laboratory values includ ed a white blood cell count of 23. 5 . Blood culture, urinalysis, and cerebrospinal fluid testing disclosed no evid ence of bacterial invasion . Magnetic resonance imaging (MRI) revealed the presence of a large mass in the midp ortion of the tongue, with an area of central necrosis and a suggestio n of an inferior extension into the floor of the mouth (figure I).
The mass was excised through a horizontal incision on the ventral surface of the tongue, after which a blunt dissection was used to expose the encapsulated midline cystic lesion, which proved to have a posterior tract. The mass was removed in its entirety. A Gram ' s stain of the purulent material in the cyst revealed numerou s gramsensitive cocci and a few gram-negative rods . Final cultures grew streptococcus. A yeast organism was cultured. The final patholog y revealed that the lesion was a dermoid cyst of the dermoid type. The patient recovered without compli cation and was discharged 4 day s postoperatively. He has remained well at 2-year followup.
Case 2. A 17-year-old girl with a history of von WiIIebrand' s disea se and pseudocholinesterase deficiency was referred to our department with a I-year history of a progressively enl arging tongue mass. She denied experiencing any respiratory distress, pain, discharge from the mass, or fever.
The physical exa mination was unremarkable except for a slightly tender tongue and the mass protruding from the dorsal surface . MRI demonstrated a 4 x 3.1 x 1.9-cm cystic mass in the midportion of the tongue inferiorly, with no extension into the posterior aspect (figure 2). Fine-needle aspira tion yielded 25 ml of slightly milky fluid, which suggested a diagnosis of dermoid cyst.
The patient underwent surgery via the transoral route under general anesthesia delivered by nasotracheal intubation. A vertic al incision was made along the ventral midline raphe of the tongue. An encapsulated mass measuring 5 x 6 em was dissected from the tongue base and intrinsic tongue musculature. Because of the history of von WiIIebrand ' s disease, a Hemovac drain was placed.
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Histopathologic examination revealed that the cyst was lined with keratinized squamous epithelium, which contained skin adnexal sebaceous glands and hair follicles , both of which are consistent with a dermoid cyst ( figure  3) . Her speech and deglutition were norm al after surgery. She has done well 2 years following surgery.
Discussion
The tongue comprises two parts that have different embryologic origins; the anterior two-thirds of the tongue arise from the ectoderm and the posterior one-third from the endoderm. Formation of the tongue begins in the human embryo during week 4 of gestation. The anterior two -thirds originates from the paired lateral lingual swellings that are contributed by the first branchial arch. These swellings subsequently fuse at the midline and join with the tuberculum impar. The remaining posterior one-third of the tongue arises from a second swelling (the hypobranchial eminence or copula), which is made up of mesoderm of the second, the third, and a portion of the fourth pharyngeal arches. The sulcus terminalis , which extends along the line of circumvallate papillae, demarcates the junction of the anterior and posterior portions of the tongue. At 7 weeks of gestation, the intrin sic musculature of the tongue is formed by the first four occipital somites, which are innervated by the hypoglossal nerve.'
Congenital dermoid cyst s are believed to arise from epithelial debris or rests that become trapped during the Volu me 79 , Number 5 Figur e 1. Case 1: Axial Tl -weighted MR1 shows all irregular tongue mass that is isoint ense to mu scle and has a hyperintense rim (A) . Axial (B) and sagittal (C) T2-w eight ed images sho w that the mass has Ghyperintense center GildGhypointense rim. Not e the inflammatory changes about the mass (arrow, B) and its location supe rior to the myloh yoid muscle (arrow, C). midline fusion of the branchial arches.' Some of these trapped cells are totipotential blastomeres that can develop into any of the three germ layers . Acquired dermoid cysts arise from epithelium implanted during trauma, and they often occur at sites away from the midline .' According to Meyer, dermoid cyst s are histopathologically classified as epidermoid, dermoid, or teratoid.' The epidermoid type is lined with simple squamous epithelium and surrounding connective tissue. The dermoid type (which was the type seen in our two patien ts) is an epithelium-lined cyst that contains skin appendages. The teratoid type is also epithelium-lined, and it con tains mesodermal or endodermal elements such as muscle , bo nes, teeth, and mucous mernbranes.v' Of the 15 earlierreported cases, seven were epidermoid cysts, four were dermoid cysts , and four were terato mas.'
The diffe rential diagnosis of a lingual mass includes der moid cyst , lingual thyroid, cystic hygroma, ranula, abscess, and congenital retention cyst of the sublingual gland. Of all dermoids, 6.9% occur in the head and neck are a, and 23% of these are located in the floor of the mouth." They are very rarely located in the tongue. Dermoid cysts in the floor of the mouth can appear in two different ways, depen ding on their relatio nship to the mylohyoid muscle ; cys ts superior to this muscle are seen as intraoral swelling, while those inferior to it manifest as swe lling in the midline of the neck.?
Patients with an intraling ual der moid cyst have diffe rent types of signs and symptoms, including asymptomatic For more information Circle 112 on Reader Service Card tongue enlargeme nt, feeding difficulties (infants), and recurre nt infection, with or without sinus fistulae. When cysts become large enough, patients can become unable to close the mouth or chew and spea k normally. MRI and computed tomograph y (CT) can delineate the internal arc hitecture and reveal the relationship of the cyst to the mylohyoid muscle. Dermoid cysts typically appear as well-circumscribed unilocular masses that are either purely cystic or heterogenous because of the presence of cholesterol, desquamated epithelial debris, and skin appendages. CT will typically show a midline unilocul ar mass with a well-defined capsu le that can be enhanced with contras t material. MRI characteristics are more variable, and dermoid cysts are usually iso-or hypointense to muscle on Tl-weighted images and hyperintense or heteroge nous on T2-weighted images , depending on their interna l content.
Treatment is complete surgical removal, usually through an incision in the ventral surface of the tongue. Whil e making this incision, the surgeo n should take care to avoid both Wharton' s ducts. No recurre nce has been reported. Marsupialization has been performed with success in cases when excision of the entire cyst was not feasible." Volume 79, Number 5
